Home > Boards > US Listed > Medical - Drugs >

Imprimis Pharmaceuticals Inc (IMMY)

Add IMMY Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/10/2019 11:49:52 AM - Followers: 59 - Board type: Free - Posts Today: 0

Imprimis Pharmaceuticals, Inc.

Oct 22, 2015. Last month, Turing Pharmaceuticals LLC, the sole supplier of Daraprim, increased the price of this prescription drug from $13.50 per tablet to a reported $750.00 per tablet. The FDA-approved label for Daraprim indicates that it is prescribed for toxoplasmosis and other types of infections. Toxoplasmosis can be of major concern for patients with weakened immune systems such as patients with HIV/AIDS, pregnant women and children. According to the Centers for Disease Control and Prevention, pyrimethamine works to block folic acid synthesis in the parasite T. gondii, the cause of toxoplasmosis, and leucovorin helps to reverse the negative effects on bone marrow caused by this mechanism of action.

Imprimis is now offering customizable compounded formulations of pyrimethamine and leucovorin in oral capsules starting as low as $99.00 for a 100 count bottle, or at a cost of under a dollar per capsule. Compounded medications may be appropriate for prescription when a commercially-available medicine does not meet the specific needs of a patient. For ordering information, please visit www.imprimiscares.com.

Mark L. Baum, CEO of Imprimis stated, "It is indisputable that generic drug prices have soared recently. While we have seen an increase in costs associated with regulatory compliance, recent generic drug price increases have made us concerned and caused us to take positive action to address an opportunity to help a needy patient population. While we respect Turing's right to charge patients and insurance companies whatever it believes is appropriate, there may be more cost-effective compounded options for medications, such as Daraprim, for patients, physicians, insurance companies and pharmacy benefit managers to consider. This is not the first time a sole supply generic drug – especially one that has been approved for use as long as Daraprim – has had its price increased suddenly and to a level that may make it unaffordable. In response to this recent case and others that we will soon identify, Imprimis is forming a new program called Imprimis Cares which is aligned to our corporate mission of making novel and customizable medicines available to physicians and patients today at accessible prices."

Mr. Baum added, "Today, some drug prices are simply out of control and we believe we may be able to help control costs by offering compounded alternatives to several sole source legacy generic drugs. Imprimis Cares and its team of compounding pharmacists will work with physicians and their patients to ensure they have affordable access to the medicines they need from the over 7,800 generic FDA-approved drugs. Imprimis Cares, available in all 50 states, will work with all third party insurers, pharmacy benefit managers and buying groups to offer its patient specific customizable compounded drug formulations at prices that ensure accessibility and that provide a reasonable profit for Imprimis. We are here to serve our patients and their physicians. We believe that when we do a great job serving our customers, our shareholders will also benefit."

Imprimis' finished compounded drug formulations do not have an FDA-approval label for recommended use. Imprimis compounded formulations are not FDA approved and may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.

Daraprim® is a registered trademark of Turing Pharmaceuticals LLC. Imprimis is not affiliated with Turing Pharmaceuticals LLC nor Daraprim®. Daraprim® is an FDA-approved drug. Please consult with your physician regarding which prescription options are most suitable for your specific needs.


San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The company's business primarily consists of four therapeutic segments including ophthalmology, urology, sinus and integrative medicine. Imprimis dispenses compounded pharmaceuticals in all 50 states from four facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisPharma.com.


Common stock outstanding after the offering       8,391,172

Cash and cash equivalents                                            18,059,285


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#3167   moving $6.50 name change: HROW wesley_ 01/10/19 11:49:52 AM
#3166   super buy if it gets hit by the jfk 12/27/18 10:38:19 PM
#3165   IMMY - New Analyst Coverage with $10 target. ireadthefins 12/11/18 08:39:59 AM
#3164   IMMY i did sell...the PPS too ahead of TrendTrade2016 11/17/18 05:50:04 AM
#3163   Yeah---adding to more companies to the IPO/spinoff list barknbud 11/16/18 11:06:38 AM
#3162   IMMY the monster is mad and she is TrendTrade2016 11/16/18 10:20:49 AM
#3161   IMMY nice friday runner!!! TrendTrade2016 11/16/18 10:07:46 AM
#3160   IMMY///find the good ones and hold!! With the TrendTrade2016 11/16/18 08:25:27 AM
#3159   Up 17% today. Looking good here. Dennisb68 11/14/18 10:26:37 AM
#3158   Market capitalization = # common shares outstanding x ireadthefins 11/08/18 07:13:34 AM
#3157   I believe in most simple terms it comes derkampfer 11/07/18 11:59:12 PM
#3156   Question: ireadthefins 11/07/18 09:55:17 AM
#3155   Another good day. I should have bought more. Dennisb68 11/01/18 04:38:11 PM
#3154   Good find and thank you. derkampfer 10/29/18 09:16:55 AM
#3153   MELT presentation: barknbud 10/29/18 08:01:04 AM
#3152   Bought in at 3.32 and so far been Dennisb68 10/28/18 07:37:11 PM
#3151   Eton is pricing tomrw if all goes well. barknbud 10/28/18 05:45:19 PM
#3150   I must admit, I was excited listening to ireadthefins 10/27/18 03:45:08 PM
#3149   Key takeaways Q2 CC CEO Mark "it's an derkampfer 10/26/18 01:37:38 PM
#3148   balance sheet is very good here...pretty low market cap!! TrendTrade2016 10/26/18 05:46:01 AM
#3147   Technically, yes you are right the company did ireadthefins 10/26/18 01:11:56 AM
#3146   Not true. Company WAS PROFITABLE last Q. Don’t derkampfer 10/26/18 12:36:30 AM
#3145   IMMY What do you think is driving this ireadthefins 10/25/18 11:52:10 PM
#3144   big board bio buy today....IMMY watch this bio TrendTrade2016 10/25/18 04:09:25 PM
#3143   Record numbers and potentially IPOing three companies of barknbud 10/22/18 09:06:40 AM
#3142   Just came across this stock. Look's like it Dennisb68 10/17/18 03:46:13 PM
#3141   BA! BOOM! BIATCH!! Stratdan 04/11/18 07:12:55 AM
#3140   Did You Not Hear Me? This Mother Come Stratdan 03/18/18 07:37:18 AM
#3139   * * $IMMY Video Chart 01-30-18 * * ClayTrader 01/30/18 05:19:55 PM
#3138   jumped in on the pullback to $1.94 Atlanta1 01/30/18 01:24:01 PM
#3137   Apparently IMMY is owned by fitbit. Whoda thunk? mkhazel 10/20/17 09:17:50 AM
#3136   * * $IMMY Video Chart 10-19-17 * * ClayTrader 10/19/17 05:24:06 PM
#3135   huge buying opportunity on this minor dip: Hercules1 10/19/17 02:24:33 PM
#3132   *Imprimis CEO Mark Baum Tells Benzinga Co. Will Hercules1 10/19/17 01:00:03 PM
#3131   Shares of Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) got Hercules1 10/19/17 12:43:49 PM
#3130   high for the day is $2.79. Hercules1 10/19/17 11:10:29 AM
#3129   Out some 2.65 wow what a rush Awl416 10/19/17 09:55:54 AM
#3128   Thin to win wow Awl416 10/19/17 09:42:03 AM
#3127   Similar https://truenaturepharma.com/wp-content/uploads/2017/06/TNTY-Investor-De goingforittoday 06/24/17 02:47:39 PM
#3126   Longboard Capital Advisors, LLC has filed a new wiltonio 03/29/17 06:15:20 AM
#3125   Looks a lot like IMMY True Nature Expands Board, goingforittoday 02/28/17 10:32:33 AM
#3124   https://www.sec.gov/Archives/edgar/data/1360214/000149315217001109/xslF345X03/fo EmptyBones 02/05/17 06:35:50 PM
#3123   Any idea what these guys are doing now? BrazenBull 04/05/16 01:21:41 AM
#3122   Back in at 3.81 MasterBidder 02/12/16 01:36:06 PM
#3121   Sure did. trickledownfacists 12/17/15 05:36:13 PM
#3120   That Martin clown that jacked price on the MasterBidder 12/17/15 03:02:31 PM
#3119   http://www.biopharmadive.com/news/senators-mull-speedier-generics-pathway-amid-o ronk 12/10/15 11:57:39 AM
#3118   He just doesn't get it. Karma is gonna ronk 12/06/15 01:19:54 PM
#3117   Hey SG.. ronk 12/04/15 07:29:53 PM
#3116   So Imprimis used to be transdel pharmaceuticals... Was this Stock Guy777 12/04/15 06:57:48 PM
Consent Preferences